Novavax has launched phase 3 clinical trials in the United States for its coronavirus vaccine candidate, making it the fifth company to launch a massive study to determine the safety and efficacy of the shots.

“The launch of this study — the fifth investigational COVID-19 vaccine candidate to be tested in a phase 3 trial in the United States — demonstrates our resolve to end the pandemic through development of multiple safe and effective vaccines,” said Dr. Anthony Fauci, the government’s top infectious disease expert and director of the National Institute of Allergy and Infectious Diseases.

Recommended Stories

Goal is to have enough vaccines for every American by second quarter, Azar says after Moderna announcement

GlaxoSmithKline and Sanofi strike massive deal with HHS for coronavirus vaccine development

Millions of coronavirus vaccines will be ready and awaiting FDA approval by Election Day